

CLAIMS

We claim:

- 5 1. A method of treating a human or animal
 having undesirable cell proliferation comprising,
 administering to the human or animal a sufficient
 amount of a composition comprising tissue factor pathway
 inhibitor to inhibit the undesirable cell proliferation.
- 10 2. The method of Claim 1 wherein the
 undesirable cell proliferation is undesirable endothelial cell
 proliferation.
- 15 3. The method of Claim 1 wherein the
 undesirable cell proliferation is an angiogenesis-related
 disease.
- 20 4. The method of Claim 3, wherein the
 angiogenic-related disease is a disease selected from the group
 consisting of cancer, arthritis, macular degeneration, and
 diabetic retinopathy.
- 25 5. The method of Claim 1 wherein
 administration of the composition inhibits angiogenesis.
- 30 6. The method of Claim 1 wherein the tissue
 factor pathway inhibitor is a protein or peptide having the
 amino acid sequence set forth in SEQ ID NO. 1, a homolog
 thereof, or an anti-proliferative fragment thereof.
- 35 7. The method of Claim 6 wherein the
 homolog is a protein or peptide having the amino acid
 sequence set forth in SEQ ID NO. 2 or an anti-proliferative
 fragment thereof.

8. The method of Claim 6 wherein the anti-proliferative fragment contains the Kunitz-3 domain or a fragment thereof.

5

9. The method of Claim 7 wherein the anti-proliferative fragment contains the Kunitz-3 domain or a fragment thereof.

10

10. The method of Claim 1 wherein the composition comprises tissue factor pathway inhibitor and a pharmaceutically acceptable excipient, carrier or sustained-release matrix.

15

11. A composition for inhibiting cell proliferation comprising tissue factor pathway inhibitor in a pharmaceutically acceptable carrier.

20

12. The composition of Claim 11, wherein the tissue factor pathway inhibitor comprises an active fragment of tissue factor pathway inhibitor, wherein the active fragment inhibits cell proliferation.

25

13. The composition of Claim 12 wherein the active fragment inhibits endothelial cell proliferation.

30

14. The composition of Claim 12 wherein the active fragment inhibits angiogenesis.

15. The composition of Claim 12 wherein the active fragment inhibits angiogenesis-related disease.

16. The composition of Claim 15, wherein the angiogenic-related disease is a disease selected from the group consisting of cancer, arthritis, macular degeneration, and diabetic retinopathy.

5

17. The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 1.

10

18. The composition of Claim 12 wherein the active fragment is a peptide having an amino acid sequence within the amino acid sequence set forth in SEQ ID NO. 2.

15

19. The composition of Claim 11 wherein the active fragment contains the Kunitz-3 domain or a fragment thereof.

20

20. The composition of Claim 10, wherein the carrier is a sustained-release matrix.